Safe duration of postoperative monitoring for malignant hyperthermia susceptible patients

被引：7
|
作者：
Pollock, N [1 ]
Langton, E [1 ]
Stowell, K [1 ]
Simpson, C [1 ]
McDonnell, N [1 ]
机构：
[1] Palmerston N Hosp, Dept Anaesthesia & Intens Care, Palmerston North, New Zealand
来源：
ANAESTHESIA AND INTENSIVE CARE | 2004年 / 32卷 / 04期
关键词：
monitoring; postoperative; malignant hyperthermia; post-anaesthetic care unit; non-triggering anaesthesia;
D O I：
10.1177/0310057X0403200407
中图分类号：
R614 [麻醉学];
学科分类号：
100217 ;
摘要：
Postoperative management of malignant hyperthermia (MH) susceptible patients has changed substantially over the last 20 years, with many patients now managed as day cases. Our previous policy was to monitor known MH susceptible patients (and relatives of known MH susceptible individuals not yet investigated by muscle biopsy) for four hours in the Post Anaesthetic Care Unit. However, anaesthetic literature reports suggest that MH reactions usually commence within one hour of anaesthesia. For this reason we conducted a retrospective review of Post Anaesthetic Care Unit data in 254 MH susceptible/related patients treated between 1991 and late 2000. On the basis of this review we instituted a policy change and reduced our monitoring time to one hour in the Post Anaesthetic Care Unit with a further 1.5h in a step-down unit if indicated. A prospective study in a further 68 MH susceptible/related patients showed that no MH reactions were missed due to the shorter monitoring period.
引用
收藏
页码：502 / 509
页数：8
相关论文
共 50 条
  • [21] In-vitro effects of cocaine in malignant hyperthermia susceptible patients
    Weisshorn, R
    Wappler, F
    Scholz, J
    Fiege, M
    Esch, JSA
    ANESTHESIOLOGY, 1999, 91 (3A) : U216 - U216
  • [22] ANESTHESIA IN A PATIENT SUSCEPTIBLE TO MALIGNANT HYPERTHERMIA
    SCHUH, FT
    MAIER, C
    ANAESTHESIST, 1982, 31 (05): : 245 - 247
  • [23] Management of malignant hyperthermia susceptible parturients
    Pollock, NA
    Langton, EE
    ANAESTHESIA AND INTENSIVE CARE, 1997, 25 (04) : 398 - 407
  • [24] Consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients from the European Malignant Hyperthermia Group
    Rueffert, Henrik
    Bastian, Boerge
    Bendixen, Diana
    Girard, Thierry
    Heiderich, Sebastian
    Hellblom, Anna
    Hopkins, Philip M.
    Johannsen, Stephan
    Snoeck, Marc M.
    Urwyler, Albert
    Glahn, Klaus P. E.
    BRITISH JOURNAL OF ANAESTHESIA, 2021, 126 (01) : 120 - 130
  • [25] MALIGNANT HYPERTHERMIA - IS ETOMIDATE SAFE
    SURESH, MS
    NELSON, TE
    ANESTHESIA AND ANALGESIA, 1985, 64 (04): : 420 - 424
  • [26] PREOPERATIVE AND POSTOPERATIVE MALIGNANT HYPERTHERMIA
    DESMONTS, JM
    DENTAN, M
    NOUVELLE PRESSE MEDICALE, 1972, 1 (07): : 465 - &
  • [27] ANALYSIS OF SARCOPLASMIC-RETICULUM PROTEINS IN PATIENTS SUSCEPTIBLE TO MALIGNANT HYPERTHERMIA
    OKU, S
    LIEW, CC
    BRITT, BA
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 1983, 60 (01) : 127 - 135
  • [28] DEFICIENT FUNCTION OF THE SARCOPLASMIC-RETICULUM IN PATIENTS SUSCEPTIBLE TO MALIGNANT HYPERTHERMIA
    CONDRESCU, M
    LOPEZ, JR
    MEDINA, P
    ALAMO, L
    MUSCLE & NERVE, 1987, 10 (03) : 238 - 241
  • [29] SHOULD MALIGNANT HYPERTHERMIA-SUSCEPTIBLE PATIENTS UNDERGO MUSCLE BIOPSY
    HINKLE, AJ
    ANESTHESIOLOGY, 1994, 80 (03) : 708 - 708
  • [30] Dantrolene in malignant hyperthermia (MH)-susceptible patients with exaggerated exercise stress
    Gronert, GA
    ANESTHESIOLOGY, 2000, 93 (03) : 905 - 905
12345